文献速递眼底病与葡萄膜炎

抗VEGF单药与维替泊芬光动力联合抗VEGF治疗新生血管性AMD的Meta分析

Anti-VEGF Monotherapy Versus Photodynamic Therapy and Anti-VEGF Combination Treatment for Neovascular Age-Related Macular Degeneration: A Meta-Analysis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

该Meta分析纳入16项随机对照试验,比较抗VEGF单药与维替泊芬光动力疗法(PDT)联合抗VEGF治疗新生血管性年龄相关性黄斑变性(AMD)的疗效与安全性,单药组587例、联合组673例。两组研究终点最佳矫正视力(BCVA)、中心视网膜厚度(CRT)及BCVA提升≥15个字母的患者比例均无统计学差异,但联合治疗所需抗VEGF注射次数更少。

要点

  • 联合治疗在BCVA与CRT结局上与单药相当,但可减少抗VEGF注射次数
  • 标准能量PDT联合组研究终点CRT较单药组更薄
  • 减低能量PDT联合组所需抗VEGF注射次数少于单药组

核心结论

  • 维替泊芬PDT联合抗VEGF治疗在BCVA提升与CRT下降方面与抗VEGF单药治疗相当,联合减低能量PDT可能减少所需抗VEGF注射次数。

研究设计与样本

  • 随机对照试验的Meta分析,共纳入16项研究,单药组587例、联合治疗组673例。

主要发现

  • 两组研究终点BCVA、CRT及BCVA提升≥15个字母的患者比例均无统计学差异。
  • 联合治疗所需抗VEGF注射次数少于单药治疗。
  • 标准能量PDT联合组研究终点CRT较单药组更薄(WMD:17.256;95%CI:5.423∼29.089;P = 0.004)。
  • 减低能量PDT联合组所需抗VEGF注射次数少于单药组(WMD:3.217;95%CI:2.798∼3.636;P < 0.001)。
  • 标准能量PDT联合组与单药组抗VEGF治疗次数无统计学差异(WMD:0.23;95%CI:-0.016∼0.475;P = 0.067)。

关键数值与推荐

  • 标准能量PDT联合治疗组研究终点CRT较单药组薄,WMD为17.256(95%CI:5.423∼29.089;P = 0.004)。
  • 减低能量PDT联合治疗组抗VEGF注射次数较单药组少,WMD为3.217(95%CI:2.798∼3.636;P < 0.001)。
  • 标准能量PDT联合组与单药组抗VEGF治疗次数比较,WMD为0.23(95%CI:-0.016∼0.475;P = 0.067)。

临床怎么用

  • 新生血管性AMD选择联合方案时,可预期BCVA与CRT结局与抗VEGF单药相当。
  • 对需减少注射负担的患者,可考虑联合减低能量PDT以减少抗VEGF注射次数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to compare the efficacy and safety of anti-VEGF monotherapy with verteporfin photodynamic therapy (PDT) and anti-VEGF combination treatment in neovascular AMD. METHODS: This study used a meta-analysis of randomized controlled trials. RESULTS: We included a total of 16 studies that included 587 patients in the monotherapy group and 673 in the combination treatment group. There was no statistical difference between best corrected visual acuity (BCVA) and central retinal thickness (CRT) at end of the study and the proportions of patients who gained ≥15 BCVA letters between the two treatment groups. Nevertheless, combination therapy required fewer anti-VEGF injections than monotherapy. Subgroup analyses showed that CRT at end of the study was thinner in the standard-fluence (SF) PDT combination therapy group than in the monotherapy group (weighted mean difference [WMD]: 17.256; 95% confidence interval [CI]: 5.423∼29.089; P = 0.004). The reduced-fluence (RF) PDT combination therapy group required fewer anti-VEGF injections than the monotherapy group (WMD: 3.217; 95% CI: 2.798∼3.636; P < 0.001), while the number of anti-VEGF treatments between the SF PDT combination therapy and monotherapy groups was not statistically different (WMD: 0.23; 95% CI: -0.016∼0.475; P = 0.067). In the combination therapy group, there was no difference between the PDT + anti-VEGF versus anti-VEGF retreatment regimens. CONCLUSIONS: This study indicates that verteporfin PDT and anti-VEGF combination therapy is effective for achieving BCVA gain and CRT reduction comparable with that of anti-VEGF monotherapy. Combination therapy with RF PDT can potentially decrease the number of anti-VEGF injections needed.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Gao Y, Yu T, Zhang Y, et al. Anti-VEGF Monotherapy Versus Photodynamic Therapy and Anti-VEGF Combination Treatment for Neovascular Age-Related Macular Degeneration: A Meta-Analysis. Invest Ophthalmol Vis Sci. 2018. PMID: 30372759. doi:10.1167/iovs.17-23747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。